Amifostine
CAS No. 20537-88-6
Amifostine ( Amifostine )
Catalog No. M13186 CAS No. 20537-88-6
Amifostine is a cytoprotective adjuvant used in Y chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents.
Purity : >98%(HPLC)
Size | Price / USD | Stock | Quantity |
5MG | 28 | In Stock |
|
10MG | 41 | In Stock |
|
25MG | 97 | In Stock |
|
50MG | 180 | In Stock |
|
100MG | 300 | In Stock |
|
200MG | 447 | In Stock |
|
500MG | 716 | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAmifostine
-
NoteResearch use only, not for human use.
-
Brief DescriptionAmifostine is a cytoprotective adjuvant used in Y chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents.
-
DescriptionAmifostine is a cytoprotective adjuvant used in Y chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents.
-
SynonymsAmifostine
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number20537-88-6
-
Formula Weight214.22
-
Molecular FormulaC5H15N2O3PS
-
Purity>98%(HPLC)
-
SolubilitySoluble in Water
-
SMILESNCCCNCCSP(O)(O)=O
-
Chemical Name2-((3-Aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester (9CI)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Guaiacin
(+)-Guaiacin has significant neuroprotective, and anti-inflammatory activities, it can inhibit cyclooxygenase (COX)-1 and COX-2.
-
Ethylmalonic acid
Ethylmalonic acid can be found in blood cerebrospinal fluid (CSF) and urine as well as in human fibroblasts prostate and skeletal muscle tissues. Moreover ethylmalonic acid is found to be associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency. Ethylmalonic acid is a non-carcinogenic potentially toxic compound.
-
8-Prenylkaempferol
8-Prenylkaempferol is an effective agent for attenuating pro-inflammatory NO induction, it may be an anti-inflammatory agent for suppressing influenza A virus-induced RANTES production acts by blocking PI3K-mediated transcriptional activation of NF-κB and IRF-3 and in part by interfering with IκB degradation which subsequently decreases NF-κB translocation.